Product Reports Resources Pricing Login Book a demo

Emergence Therapeutics

Biotech & Life Sciences · Duisburg, Germany · Founded 2019

Emergence Therapeutics is a biotechnology company focused on developing Antibody-Drug Conjugates (ADCs) for the treatment of hard-to-treat cancers. The company's lead program, ETx 22, targets Nectin 4 and aims to deliver higher efficacy with lower risk of off-target side effects and the ability to avoid tumor resistance. ETx 22 utilizes an innovative linker and payload technology to achieve these goals. Emergence Therapeutics serves patients with difficult-to-treat cancers and operates in the biopharmaceutical market. The business model revolves around the development and commercialization of first or best-in-class ADCs, driven by therapeutic need. Revenue is generated through the development and potential future sales of these ADCs, as well as possible partnerships and licensing agreements. Keywords: ADCs, Nectin 4, cancer treatment, biotechnology, biopharmaceutical, tumor resistance, innovative technology, therapeutic need, commercialization, partnerships.

Valuation $100–500M
Headcount <100
Total funding $50–100M
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Emergence Therapeutics and the history behind them.

Investors

12 investors on Emergence Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 7 investors entered at this stage
HTGF
Eurazeo
NRW.BANK
Gründerfonds Ruhr
Kurma Partners
Bpifrance
Heidelberg Pharma
Series A 5 investors entered at this stage
Pontifax Funds
Hadean Ventures
Surveyor Capital
OrbiMed
RA Capital Management

Global footprint

Where Emergence Therapeutics has talent and traffic

Workforce by country
🇩🇪 Germany · Duisburg HQ
Book a demo for the full country breakdown

Talent graph

The shape of Emergence Therapeutics's talent

Dealroom maps Emergence Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

4 team members profilednamed & role-tagged by Dealroom
13 employeestotal headcount
2 executives & foundersidentified by name
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Emergence Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about Emergence Therapeutics

An AI-synthesized read of the highest-engagement posts about Emergence Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Emergence Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles